MAPT and Alzheimer disease: The AD biomarkers were selected and defined consistent with the National Institute on Aging–Alzheimer Association Research Framework (amyloid, tau, and neurodegeneration [A/T/N]) for AD biomarkers that defines 3 general groups of biomarkers based on the nature of pathologic process that each measures.11